TMO

Business Context and Reporting Period

Company: Thermo Electron Corporation (Note: Filing reflects name prior to 2006 merger with Fisher Scientific)

Reporting Period: Quarter ended April 3, 1999 (Q1 1999)

Overview: The Company operates through four segments: Measurement and Detection, Biomedical and Emerging Technologies, Energy and Environment, and Recycling and Resource Recovery. The quarter was characterized by significant acquisition activity, specifically the purchase of Spectra-Physics AB, and ongoing restructuring efforts across multiple subsidiaries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 7% ($65.3 million) year-over-year, driven primarily by acquisitions (adding ~$130 million in revenue) and favorable currency translation.
• Profitability Decline: Net income dropped 57% to $28.3 million. This was largely due to the absence of a $39.6 million "Gain on Issuance of Stock by Subsidiaries" recorded in Q1 1998 and increased restructuring costs.
• Segment Performance:
  • Measurement and Detection: Revenues up $54.7M, but segment income margin fell to 10.6% from 14.4% due to lower-margin acquisitions and inventory revaluation charges.
  • Biomedical: Revenues up 6%, but segment income collapsed to $4.8M from $18.5M due to a $5.5M loss at Trex Medical and continued losses at ThermoLase.
  • Energy and Environment: Revenues slightly down; segment income improved to $9.3M from $7.6M, though Thermo Ecotek faces future revenue risks from power contract expirations.
• Acquisitions: The Company spent $334.5 million net of cash acquired, primarily for the acquisition of Spectra-Physics AB ($347.2 million aggregate price).

Outlook, Risks, and Unusual Items

• Restructuring Costs: The Company recorded $5.6 million in restructuring costs in Q1 1999. Additional costs are expected:
  • Trex Medical: Plans to incur ~$11 million in Q2-Q4 1999 for facility consolidation and severance.
  • Thermo Instrument: Expects ~$1.1 million in additional costs through Q3 1999.
• Thermo Ecotek Power Contracts: Significant risk exists regarding power sales agreements in California. Fixed-rate contracts with PG&E and SCE are set to expire in 2000 (or potentially mid-1999 per PG&E's assertion). A shift to "avoided cost" rates is expected to cause substantial operating losses at the Mendota and Delano plants and potential impairment of the Woodland plant assets ($3-5 million).
• ThermoLase Impairment Risk: The Company is assessing the closure or sale of day spa operations. $29.2 million of goodwill and $27 million in assets are at risk of impairment. Operating lease commitments of $24 million remain.
• Proposed Reorganization: The Company is pursuing a complex reorganization to take several majority-owned subsidiaries private (ThermoSpectra, Thermo Power, Thermo Voltek) and merge others into the parent company. Completion is subject to regulatory and shareholder approvals.
• Year 2000 Compliance: The Company expects to be compliant by October 1999. Estimated total external costs are $14 million. Risks include supply chain disruptions and potential warranty claims on older products.

Investor Verification Checklist

• Thermo Ecotek Contract Status: Verify the resolution of the dispute with PG&E regarding the termination date of fixed-rate power contracts and the projected impact on 2000 cash flows.
• Trex Medical Restructuring: Monitor the execution of the $11 million restructuring plan and its impact on Q2 and Q3 margins.
• ThermoLase Asset Realizability: Confirm the final decision on the day spa business (closure vs. sale) and the resulting impairment charges.
• Reorganization Progress: Track the status of the proposed mergers and take-private transactions, specifically the Thermo Power merger agreed to in May 1999.
• Acquisition Integration: Assess the integration of Spectra-Physics AB and the impact of inventory revaluation charges on future margins.